1. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1, 322 patients with hepatitis C infection. Issue 8 (22nd August 2017) Authors: Reau, Nancy; Robertson, Michael N.; Feng, Hwa‐Ping; Caro, Luzelena; Yeh, Wendy W.; Nguyen, Bach‐Yen T.; Wahl, Janice; Barr, Eliav; Hwang, Peggy; Klopfer, Stephanie O. Journal: Hepatology communications Issue: Volume 1:Issue 8(2017) Page Start: 757 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development of boceprevir: a first‐in‐class direct antiviral treatment for chronic hepatitis C infection. (16th July 2013) Authors: Hazuda, Daria J.; Burroughs, Margaret; Howe, Anita Y.M.; Wahl, Janice; Venkatraman, Srikanth Journal: Annals of the New York Academy of Sciences Issue: Volume 1291(2013) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Lawitz, Eric; Gane, Edward; Pearlman, Brian; Tam, Edward; Ghesquiere, Wayne; Guyader, Dominique; Alric, Laurent; Bronowicki, Jean-Pierre; Lester, Laura; Sievert, William; Ghalib, Reem; Balart, Luis; Sund, Fredrik; Lagging, Martin; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy; Howe, Anita Y M;... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1075 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Lawitz, Eric; Gane, Edward; Pearlman, Brian; Tam, Edward; Ghesquiere, Wayne; Guyader, Dominique; Alric, Laurent; Bronowicki, Jean-Pierre; Lester, Laura; Sievert, William; Ghalib, Reem; Balart, Luis; Sund, Fredrik; Lagging, Martin; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy; Howe, Anita Y M;... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1075 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Issue 8 (August 2015) Authors: Rockstroh, Jürgen K; Nelson, Mark; Katlama, Christine; Lalezari, Jay; Mallolas, Josep; Bloch, Mark; Matthews, Gail V; Saag, Michael S; Zamor, Philippe J; Orkin, Chloe; Gress, Jacqueline; Klopfer, Stephanie; Shaughnessy, Melissa; Wahl, Janice; Nguyen, Bach-Yen T; Barr, Eliav; Platt, Heather L; Rob... Journal: Lancet Issue: Volume 2:Issue 8(2015) Page Start: e319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. (31st March 2018) Authors: Asselah, Tarik; Reesink, Hendrik; Gerstoft, Jan; de Ledinghen, Victor; Pockros, Paul J.; Robertson, Michael; Hwang, Peggy; Asante‐Appiah, Ernest; Wahl, Janice; Nguyen, Bach‐Yen; Barr, Eliav; Talwani, Rohit; Serfaty, Lawrence Journal: Liver international Issue: Volume 38:Number 9(2018) Page Start: 1583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. (August 2017) Authors: Bruchfeld, Annette; Roth, David; Martin, Paul; Nelson, David R; Pol, Stanislas; Londoño, Maria-Carlota; Monsour, Howard; Silva, Marcelo; Hwang, Peggy; Arduino, Jean-Marie; Robertson, Michael; Nguyen, Bach-Yen; Wahl, Janice; Barr, Eliav; Greaves, Wayne Journal: Lancet gastroenterology and hepatology Issue: Volume 2:Number 8(2017) Page Start: 585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗